Sierra Oncology Inc (SRRA.OQ)
13 Dec 2017
Wed, Nov 8 2017
* Qtrly net loss per share, basic and diluted $0.19 Source text for Eikon: Further company coverage:
* Sierra Oncology appoints Dr. Andrew Allen to its board of directors Source text for Eikon: Further company coverage:
* sierra Oncology - establishes DNA damage response advisory committee Source text for Eikon: Further company coverage:
* on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018
- Sierra Oncology: Significant Potential Upside In 2018
- Sierra Oncology (SRRA) Presents At 2017 BIO Investor Forum - Slideshow
- Sierra Oncology (SRRA) Updates on Next Generation DDR Therapeutics - Slideshow
- How To Value Biotech Firms?
- Revisiting The ProNAi/Sierra Oncology Thesis 1 Year Later: Still Not Dead In The Water?
- Sierra Oncology (SRRA) Investor Presentation - Slideshow